Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.

Gossen, M., & Bujard, H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5547 · Cited by 4,943 · cited 1× · see citing works

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20

Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,996 · see citing works

Biosynthetic controls that determine the branching and microheterogeneity of protein-bound oligosaccharides

Schachter, H. (1986) · Biochemistry and Cell Biology · doi:10.1139/o86-026 · Cited by 526 · see citing works

Biosynthetic Controls That Determine the Branching and Microheterogeneity of Protein-Bound Oligosaccharides

Schachter, H. (1986) · Advances in experimental medicine and biology · doi:10.1007/978-1-4684-5209-9_2 · Cited by 510 · see citing works

Sequencing of N-Linked Oligosaccharides Directly from Protein Gels: In-Gel Deglycosylation Followed by Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry and Normal-Phase High-Performance Liquid Chromatography

Küster, B., Wheeler, S. F., Hunter, A. P., Dwek, R. A., & Harvey, D. J. (1997) · Analytical Biochemistry · doi:10.1006/abio.1997.2199 · Cited by 358 · see citing works

Effect of glycosylation on antibody function: implications for genetic engineering

Wright, A. M., & Morrison, S. L. (1997) · Trends in biotechnology · doi:10.1016/s0167-7799(96)10062-7 · Cited by 315 · see citing works

Quantitative aspects of the matrix‐assisted laser desorption mass spectrometry of complex oligosaccharides

Harvey, D. J. (1993) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.1290070712 · Cited by 265 · see citing works

In Pursuit of the Optimal Fed‐Batch Process for Monoclonal Antibody Production

Bibila, T. A., & Robinson, D. K. (1995) · Biotechnology Progress · doi:10.1021/bp00031a001 · Cited by 251 · see citing works

Overlapping distribution of two glycosyltransferases in the Golgi apparatus of HeLa cells.

Nilsson, T., Pypaert, M., Hoe, M. H., Slusarewicz, P., Berger, E. G., & Warren, W. G. (1993) · The Journal of Cell Biology · doi:10.1083/jcb.120.1.5 · Cited by 221 · see citing works

Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc γ receptor I and influence the synthesis of its oligosaccharide chains

Lund, J., Takahashi, N., Pound, J. D., Goodall, M. D., & Jefferis, R. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.11.4963 · Cited by 216 · see citing works

Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies

Deo, Y. M., Graziano, R. F., Repp, R., & van de Winkel, J. G. J. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)01007-4 · Cited by 213 · see citing works

Purification, cDNA cloning, and expression of UDP-N-acetylglucosamine: beta-D-mannoside beta-1,4N-acetylglucosaminyltransferase III from rat kidney.

Nishikawa, A., Ihara, Y., Hatakeyama, M., Kangawa, K., & Taniguchi, N. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)37172-8 · Cited by 195 · see citing works

Variations in Oligosaccharide−Protein Interactions in Immunoglobulin G Determine the Site-Specific Glycosylation Profiles and Modulate the Dynamic Motion of the Fc Oligosaccharides

Wormald, M. R., Rudd, P. M., Harvey, D. J., Chang, S.-C., Scragg, I. G., & Dwek, R. A. (1997) · Biochemistry · doi:10.1021/bi9621472 · Cited by 191 · see citing works

Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions.

Lifely, M. R., Hale, C., Boyce, S., Keen, M., & Phillips, J. (1995) · Glycobiology · doi:10.1093/glycob/5.8.813 · Cited by 173 · see citing works

Measurement of cytotoxicity by target cell release and retention of the fluorescent dye bis-carboxyethyl-carboxyfluorescein (BCECF)

Kolber, M. A., Quinones, R., Gress, R. E., & Henkert, P. A. (1988) · Journal of Immunological Methods · doi:10.1016/0022-1759(88)90427-9 · Cited by 132 · see citing works

Production of monoclonal antibodies in COS and CHO cells

Trill, J. J., Shatzman, A. R., & Subinay, G. (1995) · Current Opinion in Biotechnology · doi:10.1016/0958-1669(95)80092-1 · Cited by 118 · see citing works

A dominant mutation to ricin resistance in Chinese hamster ovary cells induces UDP-GlcNAc:glycopeptide beta-4-N-acetylglucosaminyltransferase III activity.

Campbell, C. E., & Stanley, P. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)90704-0 · Cited by 100 · see citing works

Effect of Structure on the Signal Strength of Oligosaccharides in Matrix-assisted Laser Desorption/Ionization Mass Spectrometry on Time-of-flight and Magnetic Sector Instruments

Naven, T. J. P., & Harvey, D. J. (1996) · Rapid Communications in Mass Spectrometry · doi:10.1002/(sici)1097-0231(199608)10:11 · Cited by 90 · see citing works

Anti-Renal-Cell Carcinoma Chimeric Antibody G250 Facilitates Antibody-Dependent Cellular Cytotoxicity with In Vitro and In Vivo Interleukin-2-Activated Effectors

Surfus, J. E., Hank, J. A., Oosterwijk, E., Welt, S., Lindstrom, M. J., Albertini, M. R., Schiller, J. H., & Sondel, P. M. (1996) · Journal of Immunotherapy · doi:10.1097/00002371-199605000-00003 · Cited by 74 · see citing works

Self-reported comprehensive health status of adult brain tumor patients using the Health Utilities Index

Whitton, A. C., Rhydderch, H., Furlong, W. J., Feeny, D. H., & Barr, R. D. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970715)80:2 · Cited by 43 · see citing works

Structural Characterization of the N-Glycans of a Humanized Anti-CD18 Murine Immunoglobulin G

Ip, C. C. Y., Miller, W. J. W., Silberklang, M., Mark, G. E., Ellis, R. W., Huang, L., Glushka, J., Vanhalbeek, H., Zhu, J., & Alhadeff, J. A. (1994) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1994.1055 · Cited by 37 · see citing works

General applications of PCR to gene cloning and manipulation

Clackson, T., Güssow, D., & Jones, P. T. (1991) · doi:10.1093/oso/9780199631964.003.0012 · Cited by 36 · see citing works

Magic Bullets at Last! Finally—Approval of a Monoclonal Antibody for the Treatment of Cancer!!!

Dillman, R. O. (1997) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.1997.12.223 · Cited by 28 · see citing works

The Use of High-Performance Anion-Exchange Chromatography and Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry to Monitor and Identify Oligosaccharide Degradation

Field, M., Papac, D. I., & Jones, A. (1996) · Analytical Biochemistry · doi:10.1006/abio.1996.0295 · Cited by 27 · see citing works

Production and characterization of a mouse/human chimeric antibody directed against human neuroblastoma

Amstutz, H., Rytz, C., Novak‐Hofer, I., Spycher, M. O., Schubiger, P. A., Blaser, K., & Morgenthaler, J. ‐. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910530127 · Cited by 23 · see citing works

Variation in N-linked carbohydrate chains in different batches of two chimeric monoclonal IgG1 antibodies produced by different murine SP2/0 transfectoma cell subclones

Bergwerff, A. A., Stroop, C. J. M., Murray, B. J., Holtorf, A., Pluschke, G., van Oostrum, J., Kamerling, J. P., & Vliegenthart, J. F. G. (1995) · Glycoconjugate Journal · doi:10.1007/bf00731335 · Cited by 23 · see citing works

Production of recombinant protein therapeutics in cultivated mammalian cells

Wurm, F. M. (2004) · Nature Biotechnology · doi:10.1038/nbt1026 · Cited by 2,032 · see citing works

Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity

Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835 · see citing works

The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity

Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413 · see citing works

Global view of human protein glycosylation pathways and functions

Schjoldager, K. T.-B. G., Narimatsu, Y., Joshi, H. J., & Clausen, H. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00294-x · Cited by 1,322 · see citing works

The Impact of Glycosylation on the Biological Function and Structure of Human Immunoglobulins

Arnold, J. N., Wormald, M. R., Sim, R. B., Rudd, P. M., & Dwek, R. A. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141702 · Cited by 1,308 · see citing works

Monoclonal antibody therapy of cancer

Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,254 · see citing works

High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR

Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J. B., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,164 · see citing works

Potent antibody therapeutics by design

Carter, P. J. (2006) · Nature reviews. Immunology · doi:10.1038/nri1837 · Cited by 1,103 · see citing works

Post-translational modifications in the context of therapeutic proteins

Walsh, G., & Jefferis, R. (2006) · Nature Biotechnology · doi:10.1038/nbt1252 · Cited by 1,007 · see citing works

Therapeutic antibodies for autoimmunity and inflammation

Chan, A. C., & Carter, P. J. (2010) · Nature reviews. Immunology · doi:10.1038/nri2761 · Cited by 840 · see citing works

Monoclonal Antibodies in Cancer Therapy

Zahavi, D. J., & Weiner, L. M. (2020) · Antibodies · doi:10.3390/antib9030034 · Cited by 845 · see citing works

Improving the efficacy of antibody-based cancer therapies

Carter, P. M. (2001) · Nature reviews. Cancer · doi:10.1038/35101072 · Cited by 833 · see citing works

Beyond binding: antibody effector functions in infectious diseases

Lu, L. L., Suscovich, T. J., Fortune, S. M., & Alter, G. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.106 · Cited by 832 · see citing works

Glycosylation as a strategy to improve antibody-based therapeutics

Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829 · see citing works

Comparing antibody and small-molecule therapies for cancer

Imai, K., & Takaoka, A. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1913 · Cited by 794 · see citing works

Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose

Ferrara, C., Grau, S., Jäger, C., Sondermann, P., Brünker, P., Waldhauer, I., Hennig, M., Ruf, A., Rufer, A. C., Stihle, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108455108 · Cited by 770 · see citing works

Structural Analysis of Human IgG-Fc Glycoforms Reveals a Correlation Between Glycosylation and Structural Integrity

Krapp, S., Mimura, Y., Jefferis, R., Huber, R., & Sondermann, P. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)01250-0 · Cited by 674 · see citing works

Optimal and consistent protein glycosylation in mammalian cell culture

Hossler, P., Khattak, S. F., & Li, Z. J. (2009) · Glycobiology · doi:10.1093/glycob/cwp079 · Cited by 669 · see citing works

Glycoprotein Synthesis: An Update

Gamblin, D. P., Scanlan, E. M., & Davis, B. G. (2008) · Chemical Reviews · doi:10.1021/cr078291i · Cited by 596 · see citing works

Glycosylation of Recombinant Antibody Therapeutics

Jefferis, R. (2005) · Biotechnology Progress · doi:10.1021/bp040016j · Cited by 526 · see citing works

From the bench to the bedside: ways to improve rituximab efficacy

Cartron, G., Watier, H., Golay, J., & Solal‐Céligny, P. (2004) · Blood · doi:10.1182/blood-2004-03-1110 · Cited by 521 · see citing works

Synthesis of Glycoproteins

Davis, B. G. (2002) · Chemical Reviews · doi:10.1021/cr0004310 · Cited by 521 · see citing works

Terminal sugars of Fc glycans influence antibody effector functions of IgGs

Raju, T. S. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.007 · Cited by 521 · see citing works

Antibody production

Birch, J. R., & Racher, A. J. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.12.006 · Cited by 477 · see citing works

Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals

Butler, M. (2005) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-005-1980-8 · Cited by 469 · see citing works

Glycans in the immune system and The Altered Glycan Theory of Autoimmunity: A critical review

Maverakis, E. M., Kim, K., Shimoda, M., Gershwin, M. E., Patel, F., Wilken, R., Raychaudhuri, S. P., Ruhaak, L. R., & Lebrilla, C. B. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2014.12.002 · Cited by 456 · see citing works

Antibody Glycosylation and Its Impact on the Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies and Fc-Fusion Proteins

Liu, L. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24444 · Cited by 428 · see citing works

Optimization of humanized IgGs in glycoengineered Pichia pastoris

Li, H., Sethuraman, N., Stadheim, T. A., Zha, D., Prinz, B., Ballew, N. L., Bobrowicz, P., Choi, B., Cook, W. J., Cukan, M. C., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1178 · Cited by 428 · see citing works

Advances in recombinant antibody manufacturing

Kunert, R., & Reinhart, D. (2016) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-016-7388-9 · Cited by 420 · see citing works

Advances in the production of human therapeutic proteins in yeasts and filamentous fungi

Gerngross, T. U. (2004) · Nature Biotechnology · doi:10.1038/nbt1028 · Cited by 409 · see citing works

Immunoglobulin G glycosylation in aging and diseases

Gudelj, I., Lauc, G., & Pezer, M. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.07.009 · Cited by 409 · see citing works

Functional roles of N ‐glycans in cell signaling and cell adhesion in cancer

Zhao, Y., Takahashi, M., Gu, J., Miyoshi, E., Matsumoto, A., Kitazume, S., & Taniguchi, N. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00839.x · Cited by 407 · see citing works

Fc glycans of therapeutic antibodies as critical quality attributes

Reusch, D., & Tejada, M. L. (2015) · Glycobiology · doi:10.1093/glycob/cwv065 · Cited by 406 · see citing works

Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality

Scallon, B. J., Tam, S. H., McCarthy, S. G., Cai, A. N., & Raju, T. S. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2006.09.005 · Cited by 397 · see citing works

Control of Recombinant Monoclonal Antibody Effector Functions by Fc <i>N</i>‐Glycan Remodeling in Vitro

Hodoniczky, J., Zheng, Y. Z., & James, D. C. (2005) · Biotechnology Progress · doi:10.1021/bp050228w · Cited by 393 · see citing works

Ovarian Cancer is Associated with Changes in Glycosylation in Both Acute-Phase Proteins and IgG

Saldova, R., Royle, L., Radcliffe, C. M., Hamid, U. M. A., Evans, R., Arnold, J. N., Banks, R. E., Hutson, R., Harvey, D. J., Antrobus, R., et al. (2007) · Glycobiology · doi:10.1093/glycob/cwm100 · Cited by 390 · see citing works

Osmoprotection in plants under abiotic stresses: new insights into a classical phenomenon

Zulfiqar, F., Akram, N. A., & Ashraf, M. (2019) · Planta · doi:10.1007/s00425-019-03293-1 · Cited by 390 · see citing works

Recombinant protein expression for therapeutic applications

Andersen, D. C., & KRUMMEN, L. A. (2002) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(02)00300-2 · Cited by 365 · see citing works

Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity

Ackerman, M. E., Crispin, M., Yu, X., Baruah, K., Boesch, A. W., Harvey, D. J., Dugast, A., Heizen, E. L., Ercan, A., Choi, I., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65708 · Cited by 359 · see citing works

IgG Fc engineering to modulate antibody effector functions

Wang, X., Mathieu, M., & Brezski, R. J. (2018) · Protein &amp; Cell · doi:10.1007/s13238-017-0473-8 · Cited by 356 · see citing works

The Carbohydrate at FcγRIIIa Asn-162

Ferrara, C., Stuart, F., Sondermann, P., Brünker, P., & Umaña, P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m510171200 · Cited by 355 · see citing works

Streptogramin-based gene regulation systems for mammalian cells

Fussenegger, M., Morris, R. P., Fux, C., Rimann, M., von Stockar, B., Thompson, C. J., & Bailey, J. E. (2000) · Nature Biotechnology · doi:10.1038/81208 · Cited by 351 · see citing works

Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond

Hogarth, P. M., & Pietersz, G. A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd2909 · Cited by 350 · see citing works

Fucose Depletion from Human IgG1 Oligosaccharide Enhances Binding Enthalpy and Association Rate Between IgG1 and FcγRIIIa

Okazaki, A., Shoji-Hosaka, E., Nakamura, K., Wakitani, M., Uchida, K., Kakita, S., Tsumoto, K., Kumagai, I., & Shitara, K. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.01.007 · Cited by 337 · see citing works

Production of pharmaceutical proteins by transgenic animals

Houdebine, L. (2008) · Comparative Immunology Microbiology and Infectious Diseases · doi:10.1016/j.cimid.2007.11.005 · Cited by 335 · see citing works

Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action

Jefferis, R. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.04.007 · Cited by 330 · see citing works

Expression of GnTIII in a recombinant anti‐CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FCγRIII

Davies, J., Jiang, L., Pan, L., LaBarre, M. J., Anderson, D., & Reff, M. (2001) · Biotechnology and Bioengineering · doi:10.1002/bit.1119 · Cited by 327 · see citing works

Defucosylated Chimeric Anti-CC Chemokine Receptor 4 IgG1 with Enhanced Antibody-Dependent Cellular Cytotoxicity Shows Potent Therapeutic Activity to T-Cell Leukemia and Lymphoma

Niwa, R., Shoji-Hosaka, E., Sakurada, M., Shinkawa, T., Uchida, K., Nakamura, K., Matsushima, K., Ueda, R., Hanai, N., & Shitara, K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2068 · Cited by 327 · see citing works

Modulating IgG effector function by Fc glycan engineering

Li, T., DiLillo, D. J., Bournazos, S., Giddens, J. P., Ravetch, J. V., & Wang, L. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1702173114 · Cited by 324 · see citing works

Advances in Mammalian cell line development technologies for recombinant protein production

Lai, T., Yang, Y., & Ng, S. (2013) · Pharmaceuticals · doi:10.3390/ph6050579 · Cited by 322 · see citing works

Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life

Saunders, K. O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01296 · Cited by 319 · see citing works

Mass spectrometry for structural characterization of therapeutic antibodies

Zhang, Z., Pan, H., & Chen, X. (2008) · Mass Spectrometry Reviews · doi:10.1002/mas.20190 · Cited by 318 · see citing works

Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells

Richards, J. O., Karki, S., Lazar, G. A., Chen, H., Dang, W., & Desjarlais, J. R. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0201 · Cited by 314 · see citing works

High-sensitivity Analytical Approaches for the Structural Characterization of Glycoproteins

Alley, W. R., Mann, B. F., & Novotný, M. V. (2013) · Chemical Reviews · doi:10.1021/cr3003714 · Cited by 307 · see citing works

Chemoenzymatic Glycoengineering of Intact IgG Antibodies for Gain of Functions

Huang, W., Giddens, J. P., Fan, S., Toonstra, C., & Wang, L. (2012) · Journal of the American Chemical Society · doi:10.1021/ja3051266 · Cited by 310 · see citing works

Monoclonal antibodies for cancer immunotherapy

Weiner, L. M., Dhodapkar, M. V., & Ferrone, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60251-8 · Cited by 305 · see citing works

Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co‐expression of heterologous β1, 4‐<i>N</i>‐acetylglucosaminyltransferase III and Golgi α‐mannosidase II

Ferrara, C., Brünker, P., Suter, T., Moser, S., Püntener, U., & Umaña, P. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20777 · Cited by 305 · see citing works

IgG glycosylation analysis

Huhn, C., Selman, M. H. J., Ruhaak, L. R., Deelder, A. M., & Wuhrer, M. (2009) · PROTEOMICS · doi:10.1002/pmic.200800715 · Cited by 301 · see citing works

Advances in the assessment and control of the effector functions of therapeutic antibodies

Jiang, X., Song, A., Bergelson, S., Arroll, T. W., Parekh, B. S., May, K. M. L., Chung, S., Strouse, R., Mire‐Sluis, A. R., & Schenerman, M. A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3365 · Cited by 299 · see citing works

Determination of critical quality attributes for monoclonal antibodies using quality by design principles

Alt, N., Zhang, T. Y., Motchnik, P., Taticek, R., Quarmby, V., Schlothauer, T., Beck, H., Emrich, T., & Harris, R. J. (2016) · Biologicals · doi:10.1016/j.biologicals.2016.06.005 · Cited by 294 · see citing works

Antibody therapeutics:

Jefferis, R. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.9.1401 · Cited by 294 · see citing works

Fc Optimization of Therapeutic Antibodies Enhances Their Ability to Kill Tumor Cells In vitro and Controls Tumor Expansion In vivo via Low-Affinity Activating Fcγ Receptors

Stavenhagen, J. B., Gorlatov, S. N., Tuaillon, N., Rankin, C. T., Li, H., Burke, S., Huang, L., Johnson, S., Bonvini, E., & Koenig, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0696 · Cited by 287 · see citing works

Enzymes in the Synthesis of Glycoconjugates

Schmaltz, R. M., Hanson, S. R., & Wong, C. (2011) · Chemical Reviews · doi:10.1021/cr200113w · Cited by 284 · see citing works

The growth and potential of human antiviral monoclonal antibody therapeutics

Marasco, W. A., & Sui, J. (2007) · Nature Biotechnology · doi:10.1038/nbt1363 · Cited by 284 · see citing works

Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease

van Erp, E. A., Luytjes, W., Ferwerda, G., & van Kasteren, P. B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00548 · Cited by 281 · see citing works

Current progress in innovative engineered antibodies

Strohl, W. R. (2017) · Protein & Cell · doi:10.1007/s13238-017-0457-8 · Cited by 282 · see citing works

Structural Comparison of Fucosylated and Nonfucosylated Fc Fragments of Human Immunoglobulin G1

Matsumiya, S., Yamaguchi, Y., Saito, J., Nagano, M., Sasakawa, H., Otaki, S., Satoh, M., Shitara, K., & Kato, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.02.034 · Cited by 278 · see citing works

Glycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments

Shivatare, S. S., Shivatare, V. S., & Wong, C. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c01032 · Cited by 260 · see citing works

Mammalian cell culture for production of recombinant proteins: a review of the critical steps in their biomanufacturing

O’Flaherty, R., Bergin, A., Flampouri, E., Mota, L. M., Obaidi, I., Quigley, A., Xie, Y., & Butler, M. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107552 · Cited by 232 · see citing works

Advances in fluorescence derivatization methods for high-performance liquid chromatographic analysis of glycoprotein carbohydrates

Anumula, K. R. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2005.09.037 · Cited by 254 · see citing works

Isotype and glycoform selection for antibody therapeutics

Jefferis, R. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.03.021 · Cited by 252 · see citing works

Chemoenzymatic Methods for the Synthesis of Glycoproteins

Li, C., & Wang, L. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00238 · Cited by 252 · see citing works

CCR4 as a novel molecular target for immunotherapy of cancer

Ishida, T., & Ueda, R. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00307.x · Cited by 248 · see citing works

Challenges in therapeutic glycoprotein production

Sethuraman, N., & Stadheim, T. A. (2006) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2006.06.010 · Cited by 247 · see citing works

Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans

Mizushima, T., Yagi, H., Takemoto, E., Shibata‐Koyama, M., Isoda, Y., Iida, S., Masuda, K., Satoh, M., & Kato, K. (2011) · Genes to Cells · doi:10.1111/j.1365-2443.2011.01552.x · Cited by 246 · see citing works

Strategies to Extend Plasma Half-Lives of Recombinant Antibodies

Kontermann, R. E. (2009) · BioDrugs · doi:10.2165/00063030-200923020-00003 · Cited by 245 · see citing works

Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment

Liu, R., Oldham, R. J., Teal, E. L., Beers, S. A., & Cragg, M. S. (2020) · Antibodies · doi:10.3390/antib9040064 · Cited by 244 · see citing works

Branched N‐glycans regulate the biological functions of integrins and cadherins

Zhao, Y., Sato, Y., Isaji, T., Fukuda, T., Matsumoto, A., Miyoshi, E., Gu, J., & Taniguchi, N. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06346.x · Cited by 237 · see citing works

Natural Killer Cell Mediated Antibody-Dependent Cellular Cytotoxicity in Tumor Immunotherapy with Therapeutic Antibodies

Seidel, U. J. E., Schlegel, P., & Lang, P. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00076 · Cited by 236 · see citing works

Role of Oligosaccharide Residues of IgG1-Fc in FcγRIIb Binding

Mimura, Y., Sondermann, P., Ghirlando, R., Lund, J., Young, S. P., Goodall, M., & Jefferis, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107478200 · Cited by 236 · see citing works

Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab

Golay, J., Roit, F. D., Bologna, L., Ferrara, C., Leusen, J. H. W., Rambaldi, A., Klein, C., & Introna, M. (2013) · Blood · doi:10.1182/blood-2013-05-504043 · Cited by 235 · see citing works

Pharmacological significance of glycosylation in therapeutic proteins

Li, H., & d′Anjou, M. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.009 · Cited by 232 · see citing works

Glycotherapy: New Advances Inspire a Reemergence of Glycans in Medicine

Hudak, J. E., & Bertozzi, C. R. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.09.010 · Cited by 228 · see citing works

N-glycomic biomarkers of biological aging and longevity: A link with inflammaging

Dall’Olio, F., Vanhooren, V., Chen, C. C., Slagboom, P. E., Wuhrer, M., & Franceschi, C. (2012) · Ageing Research Reviews · doi:10.1016/j.arr.2012.02.002 · Cited by 231 · see citing works

Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant

Zeitlin, L., Pettitt, J., Scully, C., Bohorova, N., Kim, D., Pauly, M. H., Hiatt, A., Ngo, L. H., Steinkellner, H., Whaley, K. J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108360108 · Cited by 229 · see citing works

Enhancement of the Antibody-Dependent Cellular Cytotoxicity of Low-Fucose IgG1 Is Independent of FcγRIIIa Functional Polymorphism

Niwa, R., Hatanaka, S., Shoji-Hosaka, E., Sakurada, M., Kobayashi, Y., Uehara, A., Yokoi, H., Nakamura, K., & Shitara, K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0850 · Cited by 227 · see citing works

Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity

Washburn, N., Schwab, I., Ortiz, D., Bhatnagar, N., Lansing, J. C., Medeiros, A., Tyler, S., Mekala, D., Cochran, E., Sarvaiya, H., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1422481112 · Cited by 225 · see citing works

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells

Peipp, M., van Bueren, J. J. L., Schneider‐Merck, T., Bleeker, W. K., Dechant, M., Beyer, T. D., Repp, R., van Berkel, P. H. C., Vink, T., van de Winkel, J. G. J., et al. (2008) · Blood · doi:10.1182/blood-2008-03-144600 · Cited by 223 · see citing works

Glycan profiling of anti–citrullinated protein antibodies isolated from human serum and synovial fluid

Scherer, H. U., van der Woude, D., Ioan‐Facsinay, A., Bannoudi, H. E., Trouw, L. A., Wang, J., Häupl, T., Burmester, G. R., Deelder, A. M., Huizinga, T. W. J., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27414 · Cited by 223 · see citing works

Core fucose and bisecting GlcNAc, the direct modifiers of the N-glycan core: their functions and target proteins

Takahashi, M., Kuroki, Y., Ohtsubo, K., & Taniguchi, N. (2009) · Carbohydrate Research · doi:10.1016/j.carres.2009.04.031 · Cited by 222 · see citing works

Macrolide-based transgene control in mammalian cells and mice

Weber, W., Fux, C., Baba, M. D., Keller, B., Weber, C. C., Kramer, B. P., Heinzen, C., Aubel, D., Bailey, J. E., & Fussenegger, M. (2002) · Nature Biotechnology · doi:10.1038/nbt731 · Cited by 221 · see citing works

Quality Attributes of Recombinant Therapeutic Proteins: An Assessment of Impact on Safety and Efficacy as Part of a Quality by Design Development Approach

Eon‐Duval, A., Broly, H., & Gleixner, R. (2012) · Biotechnology Progress · doi:10.1002/btpr.1548 · Cited by 218 · see citing works

A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus

Gunn, B. M., Yu, W., Karim, M. M., Brannan, J. M., Herbert, A. S., Wec, A. Z., Halfmann, P., Fusco, M. L., Schendel, S. L., Gangavarapu, K., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.07.009 · Cited by 219 · see citing works

Protein N‐Glycosylation in the Baculovirus–Insect Cell Expression System and Engineering of Insect Cells to Produce “Mammalianized” Recombinant Glycoproteins

Harrison, R. L., & Jarvis, D. L. (2006) · Advances in virus research · doi:10.1016/s0065-3527(06)68005-6 · Cited by 218 · see citing works

Amino acid and glucose metabolism in fed‐batch CHO cell culture affects antibody production and glycosylation

Fan, Y., del Val, I. J., Müller, C. R., Sen, J. W., Rasmussen, S. K., Kontoravdi, C., Weilguny, D., & Andersen, M. R. (2014) · Biotechnology and Bioengineering · doi:10.1002/bit.25450 · Cited by 217 · see citing works

Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy

Mimura, Y., Katoh, T., Saldova, R., O’Flaherty, R., Izumi, T., Mimura‐Kimura, Y., Utsunomiya, T., Mizukami, Y., Yamamoto, K., Matsumoto, T., et al. (2017) · Protein & Cell · doi:10.1007/s13238-017-0433-3 · Cited by 217 · see citing works

Marketing approval of mogamulizumab

Beck, A., & Reichert, J. M. (2012) · mAbs · doi:10.4161/mabs.20996 · Cited by 211 · see citing works

Nonfucosylated Therapeutic IgG1 Antibody Can Evade the Inhibitory Effect of Serum Immunoglobulin G on Antibody-Dependent Cellular Cytotoxicity through its High Binding to FcγRIIIa

Iida, S., Misaka, H., Inoue, M., Shibata, M., Nakano, R., Yamane-Ohnuki, N., Wakitani, M., Yano, K., Shitara, K., & Satoh, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2619 · Cited by 206 · see citing works

Therapeutic antibody expression technology

Chadd, H. E., & Chamow, S. M. (2001) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(00)00198-1 · Cited by 205 · see citing works

Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples

Reddy, V. R., Klein, C., Isenberg, D. A., Glennie, M. J., Cambridge, G., Cragg, M. S., & Leandro, M. J. (2017) · Lara D. Veeken · doi:10.1093/rheumatology/kex067 · Cited by 205 · see citing works

Influence of Variable N-Glycosylation on the Cytolytic Potential of Chimeric CD19 Antibodies

Barbin, K., Stieglmaier, J., Saul, D., Stieglmaier, K., Stockmeyer, B., Pfeiffer, M. M., Lang, P., & Fey, G. H. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000175684.28615.7b · Cited by 28 · see citing works

Expression of GnTIII in a recombinant anti‐CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FCγRIII

Davies, J., Jiang, L., Pan, L., LaBarre, M. J., Anderson, D., & Reff, M. (2001) · Biotechnology and Bioengineering · doi:10.1002/bit.1119 · Cited by 327 · see citing works

Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co‐expression of heterologous β1, 4‐<i>N</i>‐acetylglucosaminyltransferase III and Golgi α‐mannosidase II

Ferrara, C., Brünker, P., Suter, T., Moser, S., Püntener, U., & Umaña, P. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20777 · Cited by 305 · see citing works

Improved Effector Functions of a Therapeutic Monoclonal Lewis Y-Specific Antibody by Glycoform Engineering

Schuster, M., Umaña, P., Ferrara, C., Brünker, P., Gerdes, C. A., Waxenecker, G., Wiederkum, S., Schwager, C., Loibner, H., Himmler, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4212 · Cited by 91 · see citing works

Engineering of protein glycosylation in Chinese hamster ovary cells

Umaña, P. (2005) · CaltechTHESIS (California Institute of Technology) · doi:10.7907/6ceh-kt92 · Cited by 1 · see citing works